Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.77 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.77 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | PDE4A | P27815 | 3/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.54 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.54 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3680067 | 0.87 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3PDE4A | |
| SCHEMBL3677642 | 0.85 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3PDE4A | |
| SCHEMBL3674131 | 0.85 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3PDE4A | |
| SCHEMBL24995357 | 0.83 | ADORA2A (0.60) | ADORA2AADORA1ADORA2BADORA3PDE4A | |
| SCHEMBL4715461 | 0.83 | ADORA2A (0.62) | ADORA2AADORA1ADORA2BADORA3PDE4A | |
| SCHEMBL10171315 | 0.83 | ADORA2A (0.58) | ADORA2AADORA1ADORA2BADORA3PDE4A | |
| SCHEMBL3676132 | 0.83 | ADORA2A (0.66) | ADORA2AADORA1ADORA2BADORA3PDE4A | |
| SCHEMBL3684676 | 0.82 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3PDE4A | |
| SCHEMBL3684919 | 0.82 | ADORA1 (1.00) | ADORA2AADORA1ADORA2BADORA3PDE4A | |
| SCHEMBL3677848 | 0.82 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100178299-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | NORTHEASTERN UNIVERSITY (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100178299-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | NORTHEASTERN UNIVERSITY (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100178299-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | NORTHEASTERN UNIVERSITY (US) | 2010-07-15 | — | — | US | disclosed |
| EP-1349861-B1 | THIENO(3,2-d)PYRIMIDINES AND FURANO(3,2-d)PYRIMIDINES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2008-09-10 | — | — | EP | disclosed |
| US-20080153820-A1 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2008-06-26 | — | — | US | disclosed |
| US-20080153820-A1 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2008-06-26 | — | — | US | disclosed |
| US-7384949-B2 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| US-7384949-B2 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| US-7384949-B2 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178299-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | HIF1AN, HIF1A, EGLN3 | ADORA2A 6/4885ADORA1 15/4885ADORA2B 11/4885 |
| US-20080153820-A1 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists | CHRNA5, HTR5A, CHRNA6 | ADORA2A 6/4885ADORA1 37/4885ADORA2B 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.